Clinical trials: Lipemia
Metabolic Diseases, Hyperlipidemias
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
The purpose of this study is to determine safety and efficacy of mipomersen (ISIS 301012) in the reduction of total cholesterol, low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) in high risk subjects…
- Conditions
- Metabolic Diseases, Hyperlipidemias, Metabolic Disorder, Hypercholesterolemia
- Trial name
- ASSIST (NCT00707746)
- Testing
- mipomersen
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Kastle Therapeutics, LLC
Severe Hypertriglyceridemia
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG).
- Trial name
- SHASTA-3 (NCT06347003)
- Testing
- Plozasiran Injection
- Where
- 196 sites in United States, Argentina and 15 more
- Volunteers
- 446 people
- Sponsor
- Arrowhead Pharmaceuticals
Elevated LDL Cholesterol
Oat and Cholesterol
The primary objective is to assess the effect of an oat ingredient provided over 4 weeks on serum LDL cholesterol in men and women with elevated LDL-cholesterol compared to a placebo.
- Trial name
- NCT03911427
- Testing
- Active oat beverage, Control rice beverage
- Where
- Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Hypercholesterolemia
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
This study aims to characterize the single dose pharmacokinetics of PF-04950616 following subcutaneous injection to the abdomen, upper arm or the thigh.
- Trial name
- NCT02043301
- Testing
- Bococizumab (PF-04950615; RN316)
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Pfizer
Hypertension With Hyperlipidemia
Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers
study to evaluate drug-drug interaction following oral administration of telmisartan/amlodipine and atorvastatin in healthy adult volunteers
- Trial name
- NCT03461081
- Testing
- telmisartan/amlodipine and atorvastatin
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hypercholesterolemia
Combined Effect of LIMICOL and Physical Activity on LDL Cholesterol and Muscle Function.
Cardiovascular disease (CVD), foremost among which ischemic heart disease and stroke, are the leading cause of mortality and morbidity in France.
- Trial name
- L2012-12 (NCT05750602)
- Testing
- LIMICOL
- Where
- 4 sites in France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lescuyer Laboratory
Hypertriglyceridemia
Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides
The purpose is to investigate the effect of oral doses of SLx-4090 over 14 days on subjects with high triglycerides.
- Trial name
- NCT00562575
- Testing
- SLx-4090
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Response Pharmaceuticals
Hypertriglyceridemia
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia.
- Trial name
- EVOLVEII (NCT02009865)
- Testing
- Epanova, Olive Oil
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 379 people
- Sponsor
- AstraZeneca
Primary Hypercholesterolemia, Dyslipidemia
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01294683
- Testing
- Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT)
- Volunteers
- 977 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia and Hyperlipidemia, Supplementation
Evaluation of the Effects of Two Dietary Supplement Formulations on the Lipid Profile in Mild Hypercholesterolemia
A single-center, randomized, parallel-group, double-blind, placebo-controlled clinical study followed by an open-label phase to evaluate the effects of a new formulation of a supplement on lipid profile in subjects with mild…
- Trial name
- NCT06810466
- Testing
- Test Product A, Test Product B
- Where
- Italy
- Volunteers
- 99 people
- Sponsor
- IBSA Farmaceutici Italia Srl
Hypercholesterolemia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia
- Trial name
- NCT06717360
- Testing
- AG2304T, AG2304R
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Hypercholesterolemia
A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients
The purpose of this study is to evaluate adequate-dose of DW-3102 in the treatment of hypercholesterolemia patients by conducting phase 2a.
- Trial name
- NCT02368613
- Testing
- DW-3102
- Volunteers
- 64 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Obesity
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
The purpose of this study is to compare the safety and effectiveness of topiramate (64mg, 96mg, 192mg, and 384mg daily) with placebo in the treatment of obesity.
- Trial name
- NCT00236613
- Testing
- topiramate
- Volunteers
- 385 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemia
Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin
The purpose of the study is to evaluate the safety and tolerability of multiple doses of evolocumab when given as an add-on to stable statin therapy.
- Trial name
- NCT01133522
- Testing
- Evolocumab
- Volunteers
- 60 people
- Sponsor
- Amgen
Dyslipidemias, Familial Hypercholesterolemia
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers
This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT05851066
- Testing
- VSA003, 0.9% NaCl
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Visirna Therapeutics HK Limited
Hypercholesterolemia, Familial Hypercholesterolemia
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
The purpose of this study is to evaluate the efficacy and safety of enclitide chloride, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia.
- Trial name
- NCT05261126
- Testing
- Enclitide Chloride
- Where
- 63 sites in United States, Germany and 6 more
- Volunteers
- 381 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Hyperlipidemia
Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
Study design Multicenter, double-dummy, double-blinded, randomized, Phase 4 study Patients will be randomized to either a study group or a control group in a 1:1 ratio, and will be orally administered the assigned drugs Study…
- Trial name
- HM-SIM4 (NCT01564875)
- Testing
- Simvast CR, Zocor
- Where
- 7 sites in South Korea
- Volunteers
- 122 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertriglyceridemia
A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™
This was a 24-month, open-label extension study that followed an 8-week double-blind study (Study LOV111859/OM5) and an 8-week, open-label extension study (LOV111860/OM5X).
- Trial name
- NCT00891293
- Testing
- Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
- Where
- 32 sites in United States
- Volunteers
- 93 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia, Hyperlipidemia
Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)
This is a 16-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the tolerability of MK0524A versus niacin extended-release.
- Trial name
- NCT00378833
- Testing
- niacin (+) laropiprant, niacin
- Volunteers
- 1,300 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.